Anakinra for cryopyrin-associated periodic syndrome

Expert Review of Clinical Immunology

Volumn 10, Issue 1, 2014, Pages 7-18

  Koné Paut, Isabelle ^a   Galeotti, Caroline ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

anakinra; auto inflammatory diseases; canakinumab; chronic infantile neurological cutaneous and articular syndrome; cryopyrin associated periodic syndrome; familial cold auto inflammatory syndrome; familial cold urticaria; IL 1; MuckleWells syndrome; neonatal onset multisystem inflammatory disease; rilonacept; treatment

Indexed keywords

RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ARTICLE; CHEMISTRY; CINCA SYNDROME; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG LEGISLATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC);

ANTIRHEUMATIC AGENTS; CARRIER PROTEINS; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MODELS, BIOLOGICAL; SEVERITY OF ILLNESS INDEX;

EID: 84893149037     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.861325     Document Type: Article

References (52)

1. Muckle TJ, Wells M. Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome. Q. J. Med. 31, 235-248 (1962).
2. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat. Genet. 29(3), 301-305 (2001).
3. Prieur AM, Griscelli C, Lampert F et al. Chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand. J. Rheumatol. Suppl. 66, 57-68 (1987).
4. Cuisset L, Jeru I, Dumont B et al. Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France. Ann. Rheum. Dis. 70 (3), 495-499 (2011).
5. Tran TA, Koné-Paut I, Marie I, Ninet J, Cuisset L, Meinzer U. Muckle-Wells syndrome and male hypofertility: a case series. Semin. Arthritis Rheum. 42(3), 327-331 (2012).
6. Aksentijevich ID, Putnam C, Remmers EF et al. The clinical continuum of cryopyrinopathies: Novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum. 56(4), 1273-1285 (2007).
7. Stych B, Dobrovolny D. Familial cold auto-inflammatory syndrome (FCAS): characterization of symptomatology and impact on patients lives. Curr. Med. Res. Opin. 24(6), 1577-1582 (2008).
8. Lepore L, Paloni G, Caorsi R et al. Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J. Pediatr. 157(2), 310-315 (2010).
9. Kone-Paut I, Lachmann HJ, Kuemmerle-Deschner JB et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res. Ther. 13(6), R202 (2011).
10. Touitou I, Kone-Paut I. Autoinflammatory diseases. Best Pract. Res. Clin. Rheumatol. 22(5), 811-829 (2008).
11. Feldmann J, Prieur A, Quartier P et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am. J. Hum. Genet. 71(1), 198-203 (2002).
12. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1b-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20, 319-325 (2004).
13. Janssen R, Verhard E, Lankester A, ten Cate R, van Dissel JT. Enhanced interleukin-1b and interleukin-18 release in a patient with chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 50, 3329-3333 (2004).
14. Dinarello CA. Immunological and Inflammatory Functions of the Interleukin-1 Family. Annu. Rev. Immunol. 27, 519-550 (2009).
15. Milhavet F, Cuisset L, Hoffman H et al. The infevers autoinflammatory mutation online registry: update with new genes and functions. Hum. Mutat. 29(6), 803-808 (2008).
16. Rowczenio DM, Trojer H, Russell T et al. Clinical characteristics in subjects with NLRP3 V198M diagnosed at a single UK center and a review of the literature. Arthritis Res. Ther. 15(1), R30 (2013).
17. Saito M, Nishikomori R, Kambe N et al. Disease-associated CIAS1 mutations induce monocyte death, revealing low-level mosaicism in mutation-negative cryopyrinassociated periodic syndrome patients. Blood 111, 2132-2141 (2008).
18. Tanaka N, Izawa K, Saito MK et al. High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study. Arthritis Rheum. 63(11), 3625-3632 (2011).
19. Lachmann HJ, Lowe P, Felix SD et al. In vivo regulation of interleukin 1 beta in patients with cryopyrin-associated periodic syndromes. J. Exp. Med. 206(5), 1029-1036 (2009).
20. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N. Engl. J. Med. 348(25), 2583-2584 (2003).
21. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 50, 607-612 (2004).
22. Hoffman HM, Rosengren S, Boyle DL et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364, 1779-1785 (2004).
23. Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal onset multisystem inflammatory disease. Arthritis Rheum. 52, 1283-1286 (2005).
24. Goldbach-Mansky R, Dailey NJ, Canna SW et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1 inhibition. N. Engl. J. Med. 355, 581-592 (2006).
25. Leslie KS, Lachmann HJ, Bruning E et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch. Dermatol. 142, 1591-1597 (2006).
26. Maksimovic L, Stirnemann J, Caux F et al. New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes. Rheumatology 47, 309-310 (2008).
27. Kuemmerle-Deschner JB, Tyrrell PN, Koetter I et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum. 63(3), 840-849 (2011).
28. Hoffman HM, Throne ML, Amar NJ et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 58(8), 2443-2452 (2008).
29. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360(23), 2416-2425 (2009).
30. Lachmann HJ, Goodman HJ, Gilbertson JA et al. Natural history and outcome in systemic AA amyloidosis. N. Engl. J. Med. 356(23), 2361-2371 (2007).
31. Blech M, Peter D, Fischer P et al. One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1b. J. Mol. Biol. 425(1), 94-111 (2013).
32. Gul A, Tugal-Tutkun I, Dinarello CA et al. Interleukin-1b-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcets disease: an open-label pilot study. Ann. Rheum. Dis. 71(4), 563-566 (2012).
33. Aksentijevich I, Masters SL, Ferguson PJ et al. An Autoinflammatory Disease with Deficiency of the Interleukin-1-Receptor Antagonist. N. Engl. J. Med. 360(23), 2426-2437 (2009).
34. Lequerré T, Quartier P, Rosellini D et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann. Rheum. Dis. 67(3), 302-308 (2008).
35. Quartier P, Allantaz F, Cimaz R et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann. Rheum. Dis. 70(5), 747-754 (2011).
36. Ter Haar N, Lachmann H, O ? zen S et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann. Rheum. Dis. 72 (5), 678-685 (2012).
37. Bishop R, Hill S, Paul SM et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum. 62b, 258-267 (2010).
38. Neven B, Marvillet I, Terrada C et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 62(1), 258-266 (2010).
39. Sibley CH, Plass N, Snow J et al Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum. 64(7), 2375-2386 (2012).
40. Stankovic Stojanovic K, Delmas Y et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol. Dial. Transplant. 27(5), 1898-1901 (2012).
41. Olivecrona H, Alden Raboisson M, So?derberg M et al. Kineret- (anakinra) controls severe disease symptoms in patients with severe Cryopyrin-associated periodic syndrome (CAPS): up to 5 years follow-up data. Ann. Rheum. Dis. 72 (Suppl. 3), 70-71 (2013).
42. Giampietro C, Costedoat Chalumeau N et al. Anakinra in adult-onset Stills disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care. Res. 65(5), 822-826 (2013).
43. Kuemmerle-Deschner JB, Hachulla E, Cartwright R et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann. Rheum. Dis. 70(12), 2095-2102 (2011).
44. Kuemmerle-Deschner JB Wittkowski H, Tyrrell PN et al. Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. Arthritis Res. Ther. 15(3), R64 (2013
45. Hoffman HM, Throne ML, Amar NJ et al. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryinassociated periodic syndromes: results of a 72-week open-label extension study. Clin. Ther. 34(10), 2091-2103 (2012).
46. Izawa K, Hijikata A, Tanaka N et al. Detection of base substitution-type somatic mosaicism of the NLRP3 gene with >99.9% statistical confidence by massively parallel sequencing. DNA Res. 19(2), 143-152 (2012).
47. Kineret 100 mg - Anakinra: summary of products characteristics. www.ema.europa.eu/docs/en-GB/ document-library/EPAR-- -Product-Information/ human/000363/ WC500042310.pdf
48. ClinicalTrials.gov identifier: NCT00069329. http://clinicaltrials.gov/ ct2/show/ NCT00069329
49. European Medicines Agency - Science Medicines Health. www.ema.europa.eu/docs/en-GB/ document-library/PIP-decision/ WC500125667.pdf
50. Eurofever project. www.printo.it/eurofever/
51. ClinicalTrials.gov identifier: NCT01213641. http://clinicaltrials.gov/ ct2/show/ NCT01213641
52. European Medicines Agency. www.ema.europa.eu